GPCR Stock Analysis: Structure Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.815m USD | 12M Return: 202.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 41.4M
Qual. Beats: 0
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 3.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Structure Therapeutics Inc. (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for chronic diseases with unmet medical needs. Its lead candidate, GSBR-1290, is an oral biased GLP-1 receptor agonist currently in two Phase 2 trials for obesity and related conditions. The pipeline also includes ACCG-2671 and ACCG-3535 (oral amylin receptor agonists in Phase 1 for obesity), ANPA-0073 (an oral APJ receptor agonist), and LTSE-2578 (a lysophosphatidic acid 1 receptor antagonist targeting idiopathic pulmonary fibrosis). Earlier-stage programs target GIPR and glucagon receptor (GCGR) modulation for obesity and related metabolic conditions.
The company is differentiated within the biotech sector by its focus on oral small molecules, an approach that contrasts with the injectable peptide-based GLP-1 therapies that have dominated the obesity drug market. Originally incorporated in 2016 as ShouTi Inc., Structure Therapeutics is headquartered in South San Francisco, California, and operates within the GICS Biotechnology sub-industry of the Health Care sector. The company went public in early February 2023 and is classified as a mid-cap stock.
- GSBR-1290 Phase 2 obesity trial data readout approaches
- Oral GLP-1 competition intensifies from Pfizer and Lilly
- Cash runway extends as clinical trials expand across pipeline
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.11 > 0.02 and ΔFCF/TA 5.17 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.10 > 3% & CFO -154.7m > Net Income -170.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 26.16 > 1.5 & < 3 |
| Outstanding Shares: last quarter (72.4m) vs 12m ago 26.32% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.21%; Δ -0.21% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.95 (Total Current Assets 1.49b - Total Current Liabilities 57.0m) / Total Assets 1.51b |
| B: -0.36 (Retained Earnings -546.3m / Total Assets 1.51b) |
| C: -0.14 (EBIT TTM -170.0m / Avg Total Assets 1.19b) |
| D: 23.71 (Book Value of Equity 1.45b / Total Liabilities 61.0m) |
| Altman-Z'' = 28.99 = AAA |
As of July 08, 2026, the stock is trading at USD 56.63 with a total of 608,062 shares traded. Over the past week, the price has changed by +9.56%, over one month by +49.93%, over three months by +3.57% and over the past year by +202.35%.
Current recommended Stop Loss: 53.70 (which is 5.2% or 1.2 ATR below the current price).
Structure Therapeutics has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy GPCR.
- StrongBuy: 8
- Buy: 6
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 104.6 | 84.7% |
P/B = 2.5388
Revenue TTM = 0.0 USD
EBIT TTM = -170.0m USD
EBITDA TTM = -167.7m USD
Long Term Debt = 3.18m USD (estimated: total debt 5.79m - short term 2.61m)
Short Term Debt = 2.61m USD (from shortTermDebt, last quarter)
Debt = 5.79m USD (from shortLongTermDebtTotal, last quarter) (leases 5.79m already included)
Net Debt = -1.45b USD (calculated: Debt 5.79m - CCE 1.46b)
Enterprise Value = 2.36b USD (3.81b + Debt 5.79m - CCE 1.46b)
Interest Coverage Ratio = unknown (Ebit TTM -170.0m / Interest Expense TTM 0.0)
EV/FCF = -14.84x (Enterprise Value 2.36b / FCF TTM -159.2m)
FCF Yield = -6.74% (FCF TTM -159.2m / Enterprise Value 2.36b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 3.90m) / Revenue TTM)
Tobins Q-Ratio = 1.57 (Enterprise Value 2.36b / Total Assets 1.51b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 5.79m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -134.3m (EBIT -170.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 26.16 (Total Current Assets 1.49b / Total Current Liabilities 57.0m)
Debt / Equity = 0.00 (Debt 5.79m / totalStockholderEquity, last quarter 1.45b)
Debt / EBITDA = 8.66 (negative EBITDA) (Net Debt -1.45b / EBITDA -167.7m)
Debt / FCF = 9.13 (negative FCF - burning cash) (Net Debt -1.45b / FCF TTM -159.2m)
Total Stockholder Equity = 1.13b (last 4 quarters mean from totalStockholderEquity)
RoA = -14.37% (Net Income -170.6m / Total Assets 1.51b)
RoE = -15.14% (Net Income TTM -170.6m / Total Stockholder Equity 1.13b)
RoCE = -15.05% (EBIT -170.0m / Capital Employed (Equity 1.13b + L.T.Debt 3.18m))
RoIC = -9.24% (negative operating profit) (NOPAT -134.3m / Invested Capital 1.45b)
WACC = 10.25% (E(3.81b)/V(3.82b) * Re(10.27%) + D(5.79m)/V(3.82b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.27% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 21.89%
[DCF] Fair Price = unknown (Cash Flow -159.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-06-30): EPS=-0.38 | Chg30d=N/A | Revisions=+25% | Analysts=10
EPS next Quarter (2026-09-30): EPS=-0.19 | Chg30d=N/A | Revisions=-25% | Analysts=10
EPS current Year (2026-12-31): EPS=-1.43 | Chg30d=N/A | Revisions=+18% | GrowthEPS=-78.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.08 | Chg30d=N/A | Revisions=+10% | GrowthEPS=-45.3% | GrowthRev=-99.9%
[Analyst] Revisions Ratio: +15% (up=10, down=7)